Radical Nephrectomy Articles

There remain discrepancies over the factors that influence oncologic outcomes after radical nephrectomy with thrombectomy (RNTE). To assess significant predictors of oncologic outcomes after RNTE from a systematic review and meta-analysis.

The tumor stage, size, grade, and necrosis (SSIGN) score was originally defined using patients treated with radical nephrectomy (RN) between 1970 and 1998 for clear cell renal cell carcinoma (ccRCC), excluding patients treated with partial nephrectomy (PN).

SAN DIEGO, CA USA (UroToday.com) - The relationship between lipid metabolism and renal function is being increasingly recognized, although not well understood. Dr. Aditya Bagrodia and colleagues evaluated 905 patients undergoing radical nephrectomy (N=610) or partial nephrectomy (N=295) at multiple institutions.

BERKELEY, CA (UroToday.com) - In 1933, the surgeon Joseph Lazarus remarked that “there are few chapters in urology that are quite as discouraging to the surgeon as the chapter dealing with malignant tumors of the kidney.”

BERKELEY, CA (UroToday.com) - Even though the techniques reported were used in a very rare case of concomitant cancers in a native and a transplant kidney, the implications of this article can be viewed from several aspects for more practical use:

BERKELEY, CA (UroToday.com) - In this review article, we explored the contemporary role of surgical management of large renal tumors in both the clinically localized and metastatic settings.

BERKELEY, CA (UroToday.com) - The decision as to how to best treat a clinical stage I/II renal mass is often overly dependent on subjective variables such as physician experience and perception.

This study evaluated the relationship between histological markers of chronic kidney damage in patients undergoing radical nephrectomy for kidney tumours and preoperative kidney function, degree of albuminuria, and changes in glomerular volume.

To compare perioperative and oncologic outcomes for patients with clinical T1b renal cell carcinoma (RCC) following treatment with microwave ablation (MW), partial nephrectomy (PN) or radical nephrectomy (RN).

Partial nephrectomy has been persuaded as a widely accepted surgical procedure for T1a (≤ 4 cm) renal tumors. However, when treating T1b (4-7 cm) renal cell carcinoma (RCC), the "optimal" method of surgery is still debatable.

The efficacy of partial nephrectomy (PN) for T1b renal cell carcinoma (RCC) is controversial. The oncological outcomes, the change in postoperative renal function and the perioperative complications are unclear.

To evaluate the association between severe skeletal muscle deficiency or sarcopenia and disease progression, cancer-specific (CSM), and all-cause mortality (ACM) among patients with localized renal cell carcinoma (RCC) treated with radical nephrectomy (RN).

To evaluate trends in the utilization of active surveillance (AS) in a nationally representative cancer database. AS has been increasingly recognized as a strategy for patients with small renal masses (SRM), but little is known about national usage patterns.

To develop and externally validate a model that quantifies the likelihood that a pathologically node-negative patient with clear cell renal cell carcinoma (cRCC) has, indeed, no lymph node metastasis (LNM).

There is no consensus regarding a protective effect on mortality due to cause other than cancer (OCM) for patients treated with elective nephron-sparing surgery (NSS) relative to their radical nephrectomy (RN) counterparts.

To analyze the suitability for metastasis evaluation of each pathologic item on the Fourth Edition of the General Rule for Clinical and Pathologic Studies on Renal Cell Carcinoma in Japan.

We retrospectively examined 457 cases of renal operation after 2011 using the current edition of the guidelines.

The Tumor-Node-Metastasis classification of renal cell carcinoma (RCC) for pT3a tumors includes sinus fat invasion (SFI), perinephric fat invasion (PFI), renal vein invasion (RVI), and/or pelvicaliceal system invasion (PSI).

To assess the impact of lymph node dissection (LND) extent on overall survival (OS) and cancer-specific survival (CSS) in patients with pN0M0 renal cell carcinoma (RCC) treated with radical nephrectomy (RN).

Despite better renal function following nephron-sparing surgery (NSS) relative to radical nephrectomy (RN), there is no consensus with respect to the long-term sequelae associated with surgery.

To investigate the effect of surgery and the temporal pattern of two different cardiovascular event (CVe) categories after NSS versus RN.

This study aimed to evaluate the likelihood of progression to chronic kidney disease (CKD) in a cohort of geriatric Asian patients aged over 65 years who underwent either partial nephrectomy (PN) or radical nephrectomy (RN) for localised pT1 kidney tumours.

The objective of this study was to examine the effectiveness and safety of lower pole (LP) approach in retroperitoneal laparoscopic radical nephrectomy (LRN).

One hundred thirty-two renal cancer patients were scheduled for selective retroperitoneal LRN.

Neoadjuvant Targeted Molecular Therapy in the setting of localized and locally advanced renal cell carcinoma has emerged as a strategy to render primary renal tumors amenable to planned surgical resection in settings where radical resection or nephron-sparing surgery was not thought to be safe or feasible.

To compare the oncologic outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) for cT1-2/N0 renal tumors and pathologically confirmed pT1-pT3a-pNx clear cell (cc)-renal cell carcinoma (RCC).

We aimed to study recurrence-free survival after partial versus radical nephrectomy for clinical stage T1 renal cell carcinoma among all comers and those upstaged to pathologic stage T3a.

A retrospective review of 1250 patients undergoing partial nephrectomy or radical nephrectomy for clinically localized T1 renal cell carcinoma between 2006 and 2014 was performed.

Partial nephrectomy (PN) is recommended for localized T1a (≤4 cm) renal masses and is preferred over radical nephrectomy (RN) for amenable T1b/T2 (>4 cm) tumors. The objective of the current study was to assess overall survival (OS) differences between PN and RN in patients with T1 and T2 renal cell carcinoma (RCC).

We conducted a meta-analysis to evaluate the efficiency and safety of partial nephrectomy (PN) compared with radical nephrectomy (RN) for large (≥7 cm) renal tumors. A comprehensive literature search with no restrictions on language or region was conducted from August up to October in 2018 in the electronic databases of PubMed, EMBASE, the Cochrane Library, and Scopus.

The majority of RCCs occur within the 7th decade of life, uncommonly arising in adults ≤46years. We reviewed the clinicopathologic features of early-onset renal cell carcinoma (RCC) and evaluated the role of immunohistochemistry (IHC) in potentially identifying diagnoses of newly recognized RCC subtypes that may have been previously misclassified.

Positive surgical margins (PSM) are recognized as an adverse prognostic sign and are often associated with higher rates of local and systemic disease recurrence. The data regarding the oncological outcome for PSM following radical nephrectomy (RN) is limited.

To predict of the risk of cancer-specific [CSM] or other-cause mortality [OCM] for T1 kidney cancer patients aiming at identifying those who would benefit from surgery over observation.

11,192 T1 kidney cancer patients treated with surgery or observation in the SEER-Medicare database were assessed.

To develop a clinically actionable predictive model to quantitate the risk of estimated glomerular filtration rate decline to ≤45 ml/min/1.73m2 following radical nephrectomy in order to better inform decisions between radical and partial nephrectomy.

Renal cancer surgery (RCS) can adversely impact long-term function and survival. We evaluate predictors of chronic kidney disease (CKD) at 5-years and non-renal cancer mortality (NRCM) 10-years after RCS.

Birt-Hogg-Dubé syndrome (BHDS) is a rare autosomal dominant disease. It is caused by constitutional mutations in the FLCN gene. Since BHDS is a rare syndrome therefore it is unknown to many physicians.

Renal artery embolization is performed before radical nephrectomy (RN) for renal mass in order to induce preoperative infarction and to facilitate surgical intervention through decrease of intraoperative bleeding.

A clinicopathologic analysis of patients with renal cell carcinoma (RCC) and vena caval involvement diagnosed at our institution was performed. Multiple clinicopathologic parameters were examined. Fifty-three cases were identified.

There is a noticeable increase in the presentation of different types of urological malignancies at a younger age of presentation, in our institution. The objective of our study was to investigate cases presented with renal cell carcinoma, managed in the past 10 years for any possible epidemiological and cancer characteristics changes.

The rate of progression to metastatic disease in patients undergoing active surveillance for small renal tumors varies in the literature between 1% and 8%.

This study aims to examine the incidence of metastasis in small renal tumors of <4 cm in a Danish cohort.

Sunitinib/sorafenib (SU/SO), dendritic cells (DCs), or DC-cytokine-induced killer (CIK) could significantly prolong progression-free survival (PFS), 3-year overall survival (OS), or 5-year OS for patients with metastatic renal cell carcinoma (mRCC).

To compare the outcomes of robotic radical nephrectomy (RRN) to those of laparoscopic radical nephrectomy (LRN) for large renal masses.

This was a retrospective analysis of RRN and LRN cases performed for large (≥ cT2) renal masses from 2004 to 2017 and collected in the multi-institutional international database (ROSULA: RObotic SUrgery for LArge renal masses).

The aim of this study is to evaluate histological changes in tumor-parenchymal interface in clear cell renal cell carcinoma (ccRCC) after neoadjuvant axitinib treatment.

We obtained clinical and pathology materials from 23 ccRCC patients treated with neoadjuvant axitinib in a phase II clinical trial, and from 23 matched patients with ccRCC that had upfront surgery.

The decision between partial nephrectomy (PN) and radical nephrectomy (RN) may be influenced by training, practice type, or location. We sought to evaluate current opinions about the optimal management of 4-10 cm renal-cell carcinoma (RCC).

Radical nephrectomy (RN) is a standard treatment of cure for non-metastatic renal cell carcinoma (NMRCC). Long-term outcome data are limited for Pakistani population. Our aim was to assess the long-term outcomes of RCC treated with curative intent with radical nephrectomy (RN) and to study the 5 & 10years survival outcomes in patients with NMRCC who underwent radical nephrectomy.

Although robot assistance can facilitate the advantages of minimally invasive surgery, it is unclear whether it offers benefits in settings in which laparoscopic surgery has been established as the standard of care.

To assess the effect of lymph node dissection (LND), number of removed nodes (NRN) and number of positive nodes (NPN) on cancer specific mortality (CSM), in contemporary vs. historical patients, with pT2-3 Nany M0 renal cell carcinoma (RCC) treated with radical nephrectomy (RN).

We aimed to determine the prognostic role of tumor size in patients with stage pT3a renal cell carcinoma (RCC).

We analyzed our database of patients who underwent radical nephrectomy for RCC between July 2000 and December 2013.

Lymph node (LN) involvement in renal cell carcinoma (RCC) is associated with a poor prognosis. While lymph node dissection (LND) may provide diagnostic information, its therapeutic benefit remains controversial.

To determine whether use of nephron sparing surgery (NSS) for treatment of stage 1 renal cell carcinomas changed between 2009 and end 2013 in Australia.

All adult cases of renal cell carcinoma diagnosed in 2009, 2012, and 2013 were identified through the population-based Victorian Cancer Registry.

In recent years, the laparoscopic approach in oncologic urology seems more attractable to the surgeons. It is considered to have the same oncologic quality as open surgery, but is less invasive in patients.